The indication, chronic kidney disease, is a serious, progressive condition defined by decreased kidney function.
News
EMA accepts license extension submission for Invokana and Vokanamet
The decision is based on results from the landmark Phase III CREDENCE study
Multiple antibiotic courses linked to pediatric treatment failure
Data showed that those who had been given at least two previous courses were 32% more likely to fail to respond to a subsequent course.
NICE recommends antiseptics over antibiotics for impetigo
Antiseptic such as hydrogen peroxide 1% cream is ‘just as effective’ as a topical antibiotic.
HSE reimburses Braftovi combo
Eligible patients in the Republic of Ireland can potentially benefit from the combination with immediate effect.
One in seven five-year-olds don’t have MMR jabs
The lack of immunisation leaves children at high risk of measles at a time when outbreaks of the disease are occurring across the country.
Priority Review awarded to Xtandi for prostate cancer
Back in February, the companies revealed results from the Phase III ARCHES trial in men with mHSPC.
Fiasp approved for children in Europe
Novo Nordisk submitted label updates in March this year.
NICE chief executive to step down
Sir Andrew Dillon has led the organisation for 20 years.
Skyrizi bags NICE fast-track
Eligible patients in England and Wales will have access to the drug almost two months earlier.
GSK HIV combo meets main goal in Phase III study
The drug could now be administered every eight weeks compared to every four.
Scottish charity calls on minister to ‘curb obesity crisis’
The letter urges for regulation to restrict price promotions on food and drink products high in fat, sugar and salt.
Richter launches Forsteo biosimilar in EU
Both products are approved in adults for osteoporosis in various indications.
£708,000 granted for fertility research
The injection was made as the last two decades have witnessed dramatic, unpredicted changes in fertility levels.
NHS to reimburse Hemlibra
The ‘life-changing’ drug will be reimbursed for certain people with severe congenital haemophilia A.
